Oncology Biosimilars: A Primer for Clinicians

In this online activity and accompanying downloadable slideset, a biosimilars expert discusses the latest data and review options for incorporating biologic agents into individualized cancer care.
Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP

Text Module

Learn about the integration of biosimilars into oncology care with this expert-authored module reviewing biosimilar fundamentals, the regulatory review process for biosimilars, current FDA-approved biosimilars, and key trial data on biosimilars in breast and lung cancers.

Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 20, 2020 Expired: April 19, 2021

Downloadable Slideset

Download these slides with expert recommendations on the approval and integration of oncology biosimilars for clinical practice.

Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP Released: April 20, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Amgen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue